EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Outpatient diuretic intensification: a simple prognostic marker in cardiac transthyretin amyloidosis

Richard J Nies, Svenja Ney, Jasper F Nies, Katharina Seuthe, Lukas Klösges, Monique Brüwer, Stephan Nienaber, Sascha Macherey-Meyer, Matthieu Schäfer, Roman Pfister

Clinical Research in Cardiology · 2026-05 · 115 (5) · 752-762

DOI: 10.1007/s00392-025-02617-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Research in Cardiology, online erschienen am 04.03.2025. Verfasst von Richard J Nies und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinic III for Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germa…. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Heart Failure, Sodium Potassium Chloride Symporter Inhibitors, Furosemide. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Köln.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Currently, simple clinical parameters indicating disease progression are lacking in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). This study aimed to evaluate the prognostic value of outpatient diuretic intensification (ODI) in ATTR-CM patients.

Methods

This retrospective study examined ATTR-CM patients at a tertiary care center between August 1, 2020, and June 30, 2023. ODI was defined as any loop diuretic increase within 6 months after baseline visit, and its impact on all-cause mortality and hospitalization for heart failure (HF) was analyzed.

Results

Altogether, 182 patients were included (median age 80 [76; 84] years; 88% male), and 25% experienced ODI (median increase 10 [10; 40] mg furosemide equivalent). Independent predictors of ODI were higher baseline New York Heart Association (NYHA) class and polyneuropathy. Both any ODI and the magnitude of furosemide equivalent increase were significantly associated with mortality and HF hospitalization during a median follow-up of 17 months. After adjusting for baseline NYHA class and National Amyloidosis Centre stage, significantly increased risk of all-cause mortality (hazard ratio [HR] 2.38, 95% confidence interval [CI] 1.03–5.53; p = 0.043) and HF hospitalization (HR 3.27, 95% CI 1.41–7.60; p = 0.006) persisted in patients with ODI. Its prognostic value was similar in strata of age, ATTR subtype, previous cardiac decompensation, biomarkers, left ventricular ejection fraction, six-minute walk distance, and tafamidis treatment.

Conclusion

ODI occurred in one in four ATTR-CM patients within 6 months and was associated with more severe baseline amyloid organ manifestations. ODI and the magnitude of diuretic dose increase provide easily assessable clinical markers of disease progression in patient monitoring. Graphical abstract A total of 182 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR-CM) were analyzed for an increase in loop diuretic dosage within the first 6 months after the baseline visit. Twenty-five percent of the cohort experienced outpatient diuretic intensification (ODI), with independent predictors being dyspnea in higher New York Heart Association (NYHA) class and polyneuropathy (PNP). ODI was significantly associated with all-cause mortality, and its prognostic value remained consistent across various risk factors

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialHeart FailureSodium Potassium Chloride Symporter InhibitorsFurosemideCardiomyopathiesDiureticsHumansMaleFemaleRetrospective StudiesPrognosisAged, 80 and overAgedDisease Progression

Stichwörter der Autor:innen

Cardiac transthyretin amyloidosisCardiomyopathyOutpatient diuretic intensificationPrognosisRisk stratification

Substanzen

Sodium Potassium Chloride Symporter InhibitorsFurosemideDiuretics

Autor:innen und Institutionen

  • Clinic III for Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. richard.nies@uk-koeln.de.
  • Clinic III for Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
  • Department of Nephrology, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.

Förderung

  • Universitätsklinikum Köln

Zitieren

APA

Nies, R. J., Ney, S., Nies, J. F., Seuthe, K., Klösges, L., Brüwer, M., Nienaber, S., Macherey-Meyer, S., Schäfer, M., & Pfister, R. (2026). Outpatient diuretic intensification: a simple prognostic marker in cardiac transthyretin amyloidosis. Clinical Research in Cardiology, 115(5), 752-762. https://doi.org/10.1007/s00392-025-02617-4

Vancouver

Nies RJ, Ney S, Nies JF, Seuthe K, Klösges L, Brüwer M, et al. Outpatient diuretic intensification: a simple prognostic marker in cardiac transthyretin amyloidosis. Clinical Research in Cardiology. 2026;115(5):752-762. doi:10.1007/s00392-025-02617-4

BibTeX
@article{Nies2026,
  author = {Nies, Richard J and Ney, Svenja and Nies, Jasper F and Seuthe, Katharina and Klösges, Lukas and Brüwer, Monique and Nienaber, Stephan and Macherey-Meyer, Sascha and Schäfer, Matthieu and Pfister, Roman},
  title = {Outpatient diuretic intensification: a simple prognostic marker in cardiac transthyretin amyloidosis},
  journal = {Clinical Research in Cardiology},
  year = {2026},
  volume = {115},
  number = {5},
  pages = {752--762},
  doi = {10.1007/s00392-025-02617-4}
}
Kostenlos starten →